Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A first-in-human clinical study to evaluate the pharmacokinetics and bioavailability of a new MN-166 (ibudilast) parenteral formulation

Next Previous
Trial Profile

A first-in-human clinical study to evaluate the pharmacokinetics and bioavailability of a new MN-166 (ibudilast) parenteral formulation

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 10 Jan 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ibudilast (Primary)
  • Indications Acute lung injury; Alcoholism; Allergic conjunctivitis; Amyotrophic lateral sclerosis; Asthma; Cerebrovascular disorders; Multiple sclerosis; Uveal melanoma
  • Focus First in man; Pharmacokinetics
  • Sponsors MediciNova

Most Recent Events

  • 05 Jan 2023 According to MediciNova media release, the company will meet with USFDA to discuss clinical development of parenteral formulation of MN166
  • 05 Jan 2023 Status changed from not yet recruiting to completed as per MediciNova media release
  • 25 Jul 2022 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top